Key result
A novel germline PRKAR1A splice site mutation (c.349 G>T) was identified in a family with isolated PPNAD, demonstrating low penetrance and incomplete clinical expression.
Observational (n=10)
A novel PRKAR1A splice site mutation (c.349 G>T) is associated with isolated PPNAD but exhibits low penetrance and incomplete clinical expression.
Supports PRKAR1A testing consideration in isolated PPNAD families; extends variant spectrum but leaves penetrance and management implications open.
BACKGROUND/AIMS: Primary pigmented nodular adrenocortical disease (PPNAD) is associated with inactivating germline protein kinase A regulatory subunit type 1-alpha (PRKAR1A) mutations and loss of heterozygosity at the 17q22-24 locus in approximately 50% patients. PRKAR1A mutations are observed in both isolated PPNAD (iPPNAD) and Carney complex (CNC). Most mutations result in a functionally null-allele and exhibit high penetrance. We genotyped members of an extended family for a novel PRKAR1A mutation and undertook detailed phenotyping for CNC in the affected individuals. METHODS: A 10.5-year-old male was diagnosed with PPNAD; the patient's mother also had iPPNAD. A 13-year-old sibling and 7 other relatives (mean age 58.2, range 29.1-80.2 years) were referred for PRKAR1A mutation analysis. RESULTS: DNA analysis of the index case and parent revealed a novel germline heterozygous PRKAR1A mutation at the +1 position of the acceptor site of intron 3 [c.349 G>T]. The same heterozygous splice site mutation was present in the sibling with no PPNAD or CNC manifestations and 2 other individuals aged 54.9 and 57.1 years who had subclinical Cushing's syndrome but no features of CNC. CONCLUSION: We conclude that c.349 G>T, a novel splice site germline PRKAR1A defect, has low penetrance resulting in incomplete clinical expression in this kindred.
No takes yet. Share an insight, caveat, or question.
Storr et al. (2010) conducted an observational in Primary pigmented nodular adrenocortical disease (PPNAD) (n=10). PRKAR1A gene splice site mutation (c.349 G>T) was evaluated on Clinical manifestations of PPNAD or Carney complex. A novel germline PRKAR1A splice site mutation (c.349 G>T) was identified in a family with isolated PPNAD, demonstrating low penetrance and incomplete clinical expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: